HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MLYS
Mineralys Therapeutics, Inc.
There isn't enough reported data to score MLYS yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MLYS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
MLYS's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MLYS PE Valuation
MLYS has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MLYS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect MLYS's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over MLYS on earnings, with more consistent year-over-year improvement.
MLYS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.28 | -$1.31 |
| Q2 2026 | -$4.16 | -$0.58 |
| Q1 2026 | -$1.97 | +$1.78 |
| Q4 2025 | -$2.29 | +$1.37 |
| Q3 2025 | -$2.97 | +$0.29 |
| Q2 2025 | -$3.58 | -$0.88 |
| Q1 2025 | -$3.75 | -$1.57 |
| Q4 2024 | -$3.66 | -$1.67 |
MLYS is still losing money, but less than at its worst: $4.28 per share over the past year, against $5.77 at its worst in late 2022.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
MLYS Quarterly Revenue
MLYS and HIMS do not have enough comparable growth data to identify a winner.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MLYS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MLYS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$43.1M | -$14.2M |
| Q2 2026 | -$32.6M | -$2.4M |
| Q1 2026 | -$39.5M | +$6M |
| Q4 2025 | -$37.9M | +$28.9M |
| Q3 2025 | -$28.9M | +$21.4M |
| Q2 2025 | -$30.2M | -$23K |
| Q1 2025 | -$45.5M | -$26.3M |
| Q4 2024 | -$66.8M | -$37.9M |
MLYS has burned cash in almost every quarter: −$153M over the past year, against −$171M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MLYS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MLYS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5% | +4.3M shares |
| 1 year | +26% | +18.4M shares |
| 3 years | +124% | +49.2M shares |
MLYS has 89M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MLYS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -52.2x | Net Cash |
| Q3 2022 | -65.7x | Net Cash |
MLYS has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MLYS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.6 | Oversold |
| Stochastic | 2.1 | Oversold |
MLYS's weekly RSI is 28 (oversold) and its Stochastic is 2 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MLYS PE vs Healthcare Sector
MLYS has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
MLYS has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus MLYS above 0 of 4.
MLYS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.3 | 24% below |
| 20 week MA | $24.3 | 36% below |
| 50 week MA | $27.5 | 44% below |
| 100 week MA | $23.8 | 35% below |
MLYS is in a downtrend: it's below all four of its weekly moving averages, and 35% below its 100-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over MLYS on returns for 2026, with the stronger performance.
MLYS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $18.4 | $8.60 | -53% |
| 2024 | $8.60 | $12.8 | +49% |
| 2025 | $12.8 | $37.1 | +190% |
| 2026 YTD | $37.1 | $15.5 | -58% |
MLYS's yearly returns have swung widely, from +190% in 2025 to −53% in 2023. It's down 58% so far in 2026.